Brief: Cortexyme Reports Results From Phase 1 Clinical Trial Of COR588

IRulya Therapeutics

08/03/2022 13:17

March 8 (Reuters) - Cortexyme Inc  CRTX.O :
    * CORTEXYME REPORTS SAFETY AND PHARMACOKINETICS RESULTS FROM SINGLE
ASCENDING DOSE
PORTION OF ITS PHASE 1 CLINICAL TRIAL OF COR588
    * CORTEXYME INC - COR588 WELL-TOLERATED IN ALL DOSE COHORTS
    * CORTEXYME INC - HUMAN PHARMACOKINETICS SUPPORT ONCE DAILY ORAL DOSING
    * CORTEXYME INC - MULTIPLE ASCENDING DOSE DATA EXPECTED IN Q2 OF 2022

Source text for Eikon:  ID:nBw8w8pka 
Further company coverage:  CRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))